The number of isolates and susceptibilities are based on combined data from 2016-2018. Numers represent % of isolates susceptible. Isolate numbers and 95% confidence intervals are provided to gauge precision of susceptibility estimates.
Inpatient Pediatric Enterococcal Isolates (All Sites of Isolation)
|
Total Isolates |
Ampicillin |
Daptomycin |
Linezolid |
Vancomycin |
|
|
All Enterococcus isolates |
125 |
88 (81,93) |
46 (100)# (37,56) |
100 (97,100) |
94 (88,97) |
|
Enterococcus faecalis |
55 |
100 (94,100) |
51 (100)# 37,65) |
100 (94,100) |
100 (94,100) |
|
Enterococcus faecium |
8* |
42 (9,76) |
11 (100)# (0,53) |
100 (63,100) |
74 (35,97) |
|
Enterococcus gallinarum |
2* |
100 (16,100) |
0 (100)# (0,84) |
100 (16,100) |
N/A |
|
Enterococcus spp (unspecified) |
45 |
92 (80,98) |
57 (100)# (42,71) |
100 (93,100) |
98 (89,100) |
*When fewer than 30 isolates are reported, the susceptibility estimate may not be a robust estimate of population susceptibility.
# Number in parentheses represents the percentage of isolates both fully susceptible and susceptible-dose dependent to daptomycin. Susceptible-dose dependent isolates are those with MIC 2 to 4 micrograms/mL for which a high dose of daptomycin is anticipated to be active. Consult Pediatric ASP or ID for guidance on treating isolates reported as susceptible-dose dependent.